/Gilead%20Sciences%2C%20Inc_%20pills-by%20%20Marc%20Bruxelle%20via%20Shutterstock.jpg)
With a market cap of $80.6 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in drugs for HIV, liver diseases, hematology/oncology, and inflammation/respiratory diseases. Headquartered in California, its HIV franchise includes key therapies like Genvoya, Odefsey, Descovy, Biktarvy, and Truvada. The company also offers hepatitis C virus drugs like Harvoni and Epclusa and an HBV drug.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Gilead Sciences fits this criterion perfectly. The pharma company boasts a robust portfolio of innovative antiviral and antiretroviral therapies, led by its flagship drug, Truvada, and is expanding into oncology through strategic collaborations and acquisitions.